MedTrace Logo

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

NCT03270709 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2021-04-21

No results posted yet for this study

Summary

Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.

Conditions

  • HIV/AIDS
  • Vitamin D Deficiency
  • Smoker Lung

Interventions

DRUG

Vitamin D3 450,000 IU orally

Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Jenny E Han, MD, MSc · Emory University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-11
Primary Completion
2018-10-15
Completion
2018-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03270709 on ClinicalTrials.gov